Marie Bosslett, Assistant Editor

Do topical forms of PDRN actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Genetic MR links gut microbiome shifts to eczema, dermatitis, rosacea and more, spotlighting cytokines like IL‑10, IL‑18 and IL‑6 as therapeutic targets.

Black Girl Sunscreen CEO and founder reveals why daily SPF matters for deeper skin tones, tackling white cast, education gaps, and inclusive sun care testing.

In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.

Forte Biosciences' FB102 shows significant facial repigmentation in a phase 1b vitiligo trial, with gains continuing 12 weeks post-treatment and mild adverse effects.

FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.

This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.

A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.

New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.

LEADderm, led by Jennifer Soung, MD, helps dermatologists build leadership, AI readiness, and purpose-driven careers—leaving attendees energized, connected, and patient-focused.

Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.

Dermatology Times is looking back on the top stories in dermatology from the month of June.

Do nighttime collagen masks actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.

Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of June.

Raj Chovatiya, MD, PhD, MSCI, co-chair of RAD 2026, highlighted new AD science, type 2 inflammation insights, and emerging therapies—helping clinicians translate immunology advances into better patient care.

Expert guidance from RAD 2026 dispels eczema diet myths, urging symptom-based allergy testing and whole-patient atopic dermatitis care with practical skin, sleep, and lifestyle strategies.

This review of the latest dermatological studies includes insights into vitiligo, including emerging surgical techniques, the impact of social media, camouflage agents, and more.

An international survey shows vitiligo drives stigma, sun avoidance, and daily limits, urging better treatment guidance and mental health support.

Lisa Pruett, MD, FAAD, shares evidence-based acne care, debunks summer retinoid myths, and explains how Glo2Facial oxygenation and exfoliation support clearer skin and fade marks.

Discover how JAK inhibitors reshape AD care with rapid relief, smart safety screening, and emerging personalized strategies that guide real-world treatment choices.

AbbVie’s $10.9B deal adds Apogee’s long-acting IL-13 and TSLP antibodies to its portfolio, aiming for less frequent dosing in atopic dermatitis and asthma.

Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.

Mona Shahriari, MD, FAAD, urges viewing AD as systemic, guiding earlier personalized systemic therapy while optimizing topicals and shared decision-making

Mona Shahriari, MD, FAAD, shares expert insights on tailoring atopic dermatitis care, from IL‑13 biologics to promising OX40 drugs that may modify disease long term.

Explore evolving pediatric atopic dermatitis care: personalized, stepwise therapy, early-infant treatment gaps, growth monitoring, and expanding nonsteroidal options promising better outcomes.

As RAD kicks off in Nashville, Tennessee, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.